1.Steeg , P.S. (2006). Tumor metastasis : mechanistic insights and clinical ahcllenges. Nat Med 12, 895-904.
2.Morris, V.L. (1994). Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis 12, 357-367.
3.Chambers, A. F. Groom, A. C., and MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
4.Christopher, W. P. and Peter J. R. (2003). Regulation of angiogenesis by hypoxia : role of the HIF system. Nat Med Rev 9, 677-684.
5.Overall, C. M. Kleifeld, O. (2006). Validating matrix metalloproteinase as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6, 227-239.
6.Stagg, J. Johnstone, R. W. and Smyth, M. J. (2007). Form cancer immunosurveillance to cancer immunotherapy. Immunol Rev 20, 82-101.
7.Al-Mehdi, A. B. Tozawa, K. Fisher, A. B. Shientag, L. Lee, A. and Muschel, R. J. (2000). Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells : a new model for metastasis. Nat Med 6,100-102.
8.Paget, S. (1889). The distribution of secondary growths in cancer of the breast. The Lancet 133, 571-573.
9.Cabioglu, N. Yazici, M. S. Arun, B. Broglio, K. R. Hortobagyi, G. N. Price, J. E. and Sahin, A. (2005). CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 16, 5686-5693.
10.Fidler, I. J. (1995). Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87,1588-1592.
11.Scott, L. M. Priestley, G. V. and Papayannopoulou, T. (2003). Deletion of {alpha}4 integrins form adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol 23, 9349-9360.
12.Erler, J. T. Bennewith, K. L. Cox, T. R. Lang, G. Bird, D. Koong, A. Le, Q. T. and Giaccia, A. J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35–44.
13.Bok, R. A. and Small, E. J. (2002). Bloodborne biomolecular markers in
prostate cancer development and progression. Nat Rev Cancer 2, 918-926.
14.Cheng, H. C. Abdel-Ghany, M. Elble, R. C. and Pauli, B. U. (1998). Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. The Journal of biological chemistry 273, 24207-24215.
15.Cheng, H. C. Abdel-Ghany, M. and Pauli, B. U. (2003). A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. The Journal of biological chemistry 278, 24600-24607.
16.Johnson, R. C. Augustin-Voss, H. G. Zhu, D. Z. and Pauli, B. U. (1991). Endothelial cell membrane vesicles in the study of organ preference of metastasis. Cancer Res 51, 394-399.
17.Johnson, R. C. Zhu, D. Z., Augustin-Voss, H. G., and Pauli, B. U. (1993). Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J Cell Biol 121, 1423-1432.
18.Iwata, S. and Morimoto, C. (1999). CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. The Journal of experimental medicine 190, 301-306.
19.Fan, H. Meng, W. Kilian, C. Grams, S. and Reutter, W. (1997). Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. Eur. J. Biochem. 246, 243-251.
20.Von Bonin, A. Huhn, J. and Fleischer, B. (1998). Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunological reviews 161, 43-53.
21.Abbott, C. A. Gorrell, M. D. Levy, M. T., and McCaughan, G. W. (1997).
Molecular analyses of human and rat dipeptidyl peptidase IV. Advances in experimental medicine and biology 421, 161-169.
22.Hoffmann, T. Faust, J. Neubert, K. and Ansorge, S. (1993). Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS letters 336, 61-64.
23.Mest, H. J. (2006). Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement. Curr Opin Investig Drugs 7, 338-343.
24.Elgun, S. Keskinege, A. and Kumbasar, H. (1999). Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression. Psychoneuroendocrinology 24, 823-832.
25.Iwata, S. and Morimoto, C. (1999). CD26/Dipeptidyl peptidase IV in context : the different roles of a multifunctional ectoenzyme in malignant transformation. J. Exp. Med. 190, 301-305.
26.Bauvois, B. (1988). A collagen-binding glycoprotein on the surface of mouse
fibroblasts is identified as dipeptidyl peptidase IV. The Biochemical journal 252, 723-731.
27.Lloyd, C. (1979). Fibronectin: a function at the junction. Nature 279, 473-474.
28.Schwarzbauer, J. E. (1991). Alternative splicing of fibronectin : three varients, three functions. Bioessays 10, 527-533.
29.Kornblihtt, A. R., Vibe-Pedersen, K. and Baralle, F. E. (1984). Human fibronectin : cell specific alternative ,RNA splicing generates polypeptide chains differing in the number of internal repeats. Nucleic Acids Res 12, 5853-5868.
30.Williams, E. C., Janmey, P. A., Johnson, R. B., and Mosher, D. F. (1983). Fibronectin. Effect of disulfide bond reduction on its physical and functional properties. The Journal of biological chemistry 258, 5911-5914.
31.Zhu, B. C., and Laine, R. A. (1985). Polylactosamine glycosylation on human fetal placental fibronectin weakens the binding affinity of fibronectin to gelatin. The Journal of biological chemistry 260, 4041-4045.
32.Matsuura, H. Greene, T. and Hakomori, S. (1989). An
alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. The Journal of biological chemistry 264, 10472-10476.
33.Pankov, R. and Yamada, K.M. (2002). Fibronectin at a glamce. J Cell Sci 115, 3861-3863.
34.Wierzbicka-Patynowski, I. and Schwarzbauer, J. E. (2003). The ins and outs of fibronectin matrix assembly. J Cell Sci 116, 3269-3276.
35.Sharma, A. Askari, J. A. Humphries, M. J., Jones, E. Y. and Stuart, D. I. (1999). Crystal structure of a heparin- and integrin-binding segment of human fibronectin. The EMBO journal 18, 1468-1479.
36.Napoli, C. Lemieux, C. and Jorgensen, R. (1990). Introduction of a chimeric chalcone sSynthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2, 279-289.
37.Romano, N. and Macino, G. (1992). Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous
sequences. Mol Microbiol 6, 3343–3353.
38.Guo, S. and Kemphues, K. J. (1995). par-1, a gene required for establishing polarity in C. elegans embryos, encodes aputative Ser/Thr kinase that is asymmetrically distributed. Cell 81, 611-620.
39.Fire, A. (1999). RNA triggered gene silencing. Trends in Genetics 15, 358-363.
40.Bernstein, E. Caudy, A. A. Hammond, S. M. and Hannon, G. J. (2001). Role for a bidentate ribonuclease in the initiate step of RNA interference. Nature 409, 363-366.
41.Zamore, P. D. Tuschl, T. Sharp, P. A. and Bartel, D. P. (2000). RNAi：double –stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33.
42.Martinez, J. Patkaniowska, A. Urlaub, H. Luhrmann, R. and Tuschl, T. (2002). Single-standed antisense siRNAs quide target RNA cleavage in RNAi. Cell 110, 563-574.
43.Schwarz, D. S. Hutvagner, G. Du, T. Xu, Z. Aronin, N. and Zamore, P. D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208.
44.Sijen, T. Fleenor, J. Simmer, F. Thijssen, K. L. Parrish, S. Timmons, L. Plasterk, R. H. and Fire, A. (2001). On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 107, 465-476.
45.Stark, G. R. Kerr, I. M. Williams, B. R. Silverman, R. H. and Schreiber, R. D. (1998). How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264.
46.Silva, J. M., Hammond, S. M. and Hannon, G. J. (2002). RNA interference : a promising approach to antivirial therapy? Trends in Molecular Medicine 8, 505-508.
47.Tuschl T. (2002). Expanding small RNA interference. Nat Biotechnol. 20, 446-448.
48.Brummelkamp, T. R. Bernards, R. and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
49.Boden, D. Pusch, O. Le, F. Tucker, L. Shank, P. R. and Ramratnam, B. (2003). Promoter choice affects the potency of HIV-1 specific RNA interference. Nucl Acids Res 31, 5033-5038.
50.Hutvagner, G. McLachlan, J. Pasquinelli, A. E. Balint, E. Tuschl, T. and Zamore, P. D. (2001). A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA. Science 293, 834-838.
51.Yang, N. Burkholder, J. Roberts, B. Martinell, B. and McCabe, D. (1990). In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. PNAS 87, 9568-9572.
52.Robbins, P. D. Tahara, H. and Ghivizzani, S. C. (1998). Viral vectors for gene therapy. Trends. Biotechnol. 16, 35-40.
53.Mulligan, R. C. (1993). The basic science of gene therapy. Science 260, 926-936.
54.Li, C. Bowles, D. E. van Dyke, T. and Richard, J. S. (2005). Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther 12, 913-925.
55.Mackett, M. Smith, G. L. and Moss, B. (1982). Vaccinia virus: A selectable eukaryotic cloning and expression vector. PNAS 79, 7415-7419.
56.Weir, J. P. and Elkins, K. L. (1993). Replication-incompetent herpesvirus vector delivery of an interferon alpha gene inhibits human immunodeficiency virus replication in human monocytes. PNAS 90, 9140-9144.
57.Stewart, P. L. Fuller, S. D. and Burnett, R. M. (1993). Difference imaging of adenovirus : bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J 12, 2589-2599.
58.Russell, W. C. (2000). Update on adenovirus and its vectors. Journal of General Virology 81, 2573-2604.
59.Bramson, J. L. Graham, F. L. Gauldie, J. (1995). The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 6, 590-595.
60.Greber, U. F. Willetts, M. Webster, P. Helenius, A. (1993). Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75, 477-486.
61.Moran, E. (1993). Interaction of adenoviral proteins with pRB and p53. FASEB J 7, 880-885.
62.Haddada, H. Cordier, L. and Perricaudet, M. (1995). Gene therapy using adenovirus vectors. Curr Top Microbiol Immunol 199, 297-306.
63.Lieber, A. He, C. Y. Kirillova, I. and Kay, M. A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 70, 8944-8960.
64.He, T. C. Zhou, S. da Costa, L. T. Yu, J. Kinzler, K. W. Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. PNAS 95, 2509-2514.
65.McGrory, W. J. Bautista, D. S. and Graham F. L. (1988). A simple technique for the rescue of early region I mutations into infections human adenovirus type 5. Virology 163, 614-617.
66.Marrink, J. vd Geest, S. Sinnema, R. Vellenga, E. and de Vries, E. G. (1985).
Fibronectin-complex (FN-C) present in normal plasma. Thrombosis research 37,
689-692.
67.Aytac, U. Sato, K. Yamochi, T. Yamochi, T. Ohnuma, K. Mills, G. B. Morimoto, C. Dang, N. H. (2003). Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. British journal of cancer 88, 455-62.
68.Koenuma, M. Yamori, T. Tsuruo, T. (1989). Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 80, 51-8.
69.Kong, F. Garcia, A. J. Mould, A. P. Humphries, M. J. Zhu, C. (2009). Demonstration of catch bonds between an integrin and its ligand. J Cell Biol 185, 1275-1284.
70.Lotsov, V. and Stehelin, D. (1996). Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth & Differentiation 7, 629-634.
71.Han, S. W. and Roman, J. (2006). Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated byPI3-kinase and NF-κB. Oncogene 25, 4341–4349.
72.Ce’dric, G. Marcel, D. Guillaume, R. Patricia, A. Michelle, B. Markus, U. E. Jean-Paul, O. Robert, B. and Sophie, T. D. (2005). HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene 24, 1423-1433.
73.Asbury, C. L. van den Engh, G. and Uy, J. L. (2000). Polarization of scater and fluorescence s ignals in flow cytometry. Cytometry 40, 2000.
74.Huang, L. Cheng, H. C. Isom, R. Chen, C. S. Levine, R. A. and Pauli, B. U. (2008).
Protein kinase Cepsilon mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis
The Journal of biological chemistry 283, 7616-7627.
75.Zerlauth, G. Wesierska-Gadek, J. and Sauermann, G. (1988). Fibronectin observed in the nuclear matrix of HeLa tumour cells. Journal of Cell Science 89, 415-421.
76.Zardi, L. Siri, A. Carnemolla, B. Santi, L. Gardner, W. D. and Hoch, S. O. (1979). Fibronectin: a chromatin-associated protein?. Cell 3, 649-657.
77.Lin, S. Y. Makino, K. Xia, W. Matin, A. Wen, Y. Kwong, K. Y. Bourguignon, L. and Hung, M. C. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Bio 3, 802-808.
78.You, R. Klein, R. M. Zheng, M. and McKeown-Longo, P. J. (2009). Regulation of p38 MAP kinase by anastellin is independent of anastellin's effect on matrix fibronectin. Matrix Biology 28, 101–109.
79.Zhao, J. Sime, P. J. Bringas, P. J. Gauldie, J. and Warburton, D. (1998). Epithelium-specific adenoviral transfer of a dominant-negative mutant TGF-beta type II receptor stimulates embryonic lung branching morphogenesis in culture and potentiates EGF and PDGF-AA. Mech Dev 72, 89-100.
80.Cao, B. Mytinger, J. R. and Huard, J. (2002). Adenovirus mediated gene transfer to skeletal muscle. Microsc Res Tech 58, 45-51.
81.Qin, M. Escuadro, B. Dohadwala, M. Sharma, S. Batra, R. K. (2004). A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res 64, 6377–6380.
82.Shayakhmetov, D. M. Li, Z. Y. Ni, S. and Lieber, A. (2002). Targeting of adenovirus vector to tumor cells does not enable efficient transduction of breast cancer metastase. Cancer Res 62, 1063-1068.
83.Masaki, K. Merrill, E. G. Takashi, A. Susan, B. and Tito, F. (2001). Enhanced aenovirus transgene expression in malignant cells treated with the histone
deacetylase inhibitor FR901228. Cancer Res 61, 6328-6330.
84.Kurt, J. L. and Jane, S. (1999). Identification of protein-disulfide isomerase activity in fibronectin. The Journal of biological chemistry 274, 7032-7038.
85.Yvonne, L.K. Jianjie, N. and Paul, W. J. (1997). The high affinity heparin-binding domain and the V region of fibronectin mediate invasion of human oral squamous cell carcinoma cells in vitro. The Journal of biological chemistry 272, 18932-18938.
86.Lubor, B. (2004). Selectins facilitate carcinoma metastasis and heparin can prevent them. Physiology 19, 16-21.
87.Jennifer, L. S. Sharon, H. C. and Ajit Varki. (2005). Differential metastasis inhibition by clinically Rrelevant levels of heparins─Correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 11, 7003-7011.
88.沈佩蓁 (2007)。 探討內源性纖連蛋白與癌細胞表面上聚合體纖連蛋白組裝的關聯性。國立成功大學碩士論文。89.王毓瑄 (2007)。 辨認纖連蛋白胺基端區域中與第四型雙胜肽水解酶的結合位點。國立成功大學碩士論文。